Loading cancer entity…
Loading cancer entity…
Clinical trials
184 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04169763 | Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery | recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | terminated | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03452332 | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | completed | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00851643 | Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) | completed | Phase 1 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 3, 2016 | clinicaltrials |
| NCT01652794 | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00019110 | Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00842452 | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 26 | Steven Waggoner, MDOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00335998 | Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials